MetaCap

Xenetic Biosciences Inc. (XBIO)

NASDAQ: XBIOHealth CareBiotechnology: Pharmaceutical PreparationsUSD

1.40-0.14 (-9.09%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

XBIO stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$1.55
52-week range
1.25 – 4.94
Day range
1.25 – 1.56
Volume / Avg
21.76K / 73.30K
Beta
—

52-week range

$1.25$4.94

XBIO stock today

Xenetic Biosciences (XBIO) closed at $1.40 on Nov 20, down 9.09% (-$0.14), versus the S&P 500's 3.70% decline. Trading was light, with 21.76K shares changing hands, about 30% of the average daily volume. At this level, XBIO sits near the bottom of its 52-week range of $1.25 to $4.94: 71.7% below the high and 12.0% above the low.

Xenetic Biosciences has posted a net loss over the last twelve months (EPS of -$1.55), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Xenetic Biosciences

Company profile

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer growth, metastasis, and progression, and contribute to immunotherapy, chemotherapy, and radiotherapy resistance. The company's product pipeline includes XBIO-015 for the treatment of pancreatic carcinoma and solid tumors; XBIO-020 for the treatment of solid tumors; and ErepoXen, which uses PolyXen platform technology for the treatment of anemia in chronic kidney disease (CKD) patients.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. James F. Parslow
Headquarters
Framingham, MA
Employees
2

Financial highlights

Full financials

In fiscal 2025, Xenetic Biosciences generated $3.0 million in revenue, up 19.0% from fiscal 2024. Xenetic Biosciences reported a net loss of $2.7 million, compared with a loss of $4.0 million a year earlier. Operating margin was -95.2%.

Xenetic Biosciences annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$2.98M$2.50M$2.54M$1.71M$1.16M
Growth+19.04%-1.56%+48.80%+47.06%+165.64%
Net income$-2.68M$-3.96M$-4.13M$-6.55M$-5.65M
EPS (diluted)$-1.58$-2.57$-2.71$-4.61$-0.55

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-0.72 vs —

Xenetic Biosciences peers

Health Care sector
XBIO peer companies
CompanyPrice% ChgMarket capCompare
APREAprea Therapeutics Inc.0.229-53.56%$3.25Mvs XBIO
XTLBXTL Biopharmaceuticals Ltd. ADR1.37-5.84%$3.37Mvs XBIO
NRSNNeuroSense Therapeutics Ltd.1.28+1.59%$3.19Mvs XBIO
KPRXKiora Pharmaceuticals Inc.0.7202-12.28%$3.19Mvs XBIO
MDCXMedicus Pharma Ltd.1.14-2.16%$3.16Mvs XBIO
AZTRAzitra Inc0.5168-2.75%$3.13Mvs XBIO
GELSGelteq Limited0.2701-3.74%$3.11Mvs XBIO
SKYESkye Bioscience Inc.0.70-11.03%$3.10Mvs XBIO

Indexes, lists and sector

Xenetic Biosciences stock FAQ

What is Xenetic Biosciences's stock price today?

XBIO last traded at $1.40 as of Nov 20, 4:00 PM EST, down 9.09% on the day. Prices are delayed at least 15 minutes.

Who is Xenetic Biosciences's CEO?

Mr. James F. Parslow is the chief executive officer of Xenetic Biosciences Inc., which has about 2 employees.

What is the XBIO 52-week high?

The 52-week high for XBIO is $4.94 and the 52-week low is $1.25. The stock is currently 71.7% below its high.

Compare XBIO